Do analysts recommend AKBA or KVAC?

Akebia Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 326.82%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, AKBA or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than Akebia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akebia Therapeutics $236.20M 1.03 -$5.34M -$0.11 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Do analysts rate PRQR or KVAC?

ProQR Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 227.51%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, PRQR or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than ProQR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $18.36M 13.14 -$47.73M -$0.46 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Do analysts prefer KVAC or RNA?

Avidity Biosciences has a consensus price target of $63.85, suggesting a potential upside of 368.08%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.29

Which has preferable valuation and earnings, KVAC or RNA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Avidity Biosciences N/A N/A N/A -$2.15 N/A

Is KVAC or RNA more profitable?

Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Avidity Biosciences N/A N/A N/A

Do analysts rate DTIL or KVAC?

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 314.52%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, DTIL or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than Precision BioSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precision BioSciences $45.06M 4.77 -$45.72M -$2.80 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Do analysts prefer KVAC or TNXP?

Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 80.28%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has better valuation and earnings, KVAC or TNXP?

Keen Vision Acquisition has higher earnings, but lower revenue than Tonix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Tonix Pharmaceuticals $13.11M 17.78 -$124.02M -$12.94 N/A

Keen Vision Acquisition (KVAC) Competitors

$11.51 0.00 (0.00%)

As of 08/28/2026

Compare

KVAC vs. AKBA, PRQR, RNA, DTIL, and TNXP

Should you buy Keen Vision Acquisition stock or one of its competitors? Keen Vision Acquisition's main competitors and comparable companies include Akebia Therapeutics (AKBA), ProQR Therapeutics (PRQR), Avidity Biosciences (RNA), Precision BioSciences (DTIL), and Tonix Pharmaceuticals (TNXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Keen Vision Acquisition compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Keen Vision Acquisition has lower revenue, but higher earnings than Akebia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.03	-$5.34M	-$0.11	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Akebia Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Akebia Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 326.82%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Akebia Therapeutics had 4 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 4 mentions for Akebia Therapeutics and 0 mentions for Keen Vision Acquisition. Akebia Therapeutics' average media sentiment score of 0.71 beat Keen Vision Acquisition's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akebia Therapeutics	Positive
Keen Vision Acquisition	Neutral

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Keen Vision Acquisition has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Keen Vision Acquisition's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Keen Vision Acquisition	N/A	N/A	N/A

Summary

Akebia Therapeutics beats Keen Vision Acquisition on 7 of the 12 factors compared between the two stocks.

How does Keen Vision Acquisition compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 4 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 4 mentions for ProQR Therapeutics and 0 mentions for Keen Vision Acquisition. ProQR Therapeutics' average media sentiment score of 0.99 beat Keen Vision Acquisition's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ProQR Therapeutics	Positive
Keen Vision Acquisition	Neutral

ProQR Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 227.51%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition has lower revenue, but higher earnings than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$18.36M	13.14	-$47.73M	-$0.46	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Keen Vision Acquisition has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Keen Vision Acquisition's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Keen Vision Acquisition	N/A	N/A	N/A

Summary

ProQR Therapeutics beats Keen Vision Acquisition on 7 of the 12 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Avidity Biosciences?

Keen Vision Acquisition (NASDAQ:KVAC) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

51.7% of Keen Vision Acquisition shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Avidity Biosciences	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

Avidity Biosciences has a consensus price target of $63.85, suggesting a potential upside of 368.08%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

In the previous week, Avidity Biosciences had 3 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 3 mentions for Avidity Biosciences and 0 mentions for Keen Vision Acquisition. Avidity Biosciences' average media sentiment score of 0.96 beat Keen Vision Acquisition's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Avidity Biosciences	Positive

Summary

Avidity Biosciences beats Keen Vision Acquisition on 6 of the 8 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Precision BioSciences had 3 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 3 mentions for Precision BioSciences and 0 mentions for Keen Vision Acquisition. Precision BioSciences' average media sentiment score of 0.80 beat Keen Vision Acquisition's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Precision BioSciences	Positive
Keen Vision Acquisition	Neutral

Precision BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 314.52%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Keen Vision Acquisition's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Keen Vision Acquisition	N/A	N/A	N/A

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Keen Vision Acquisition has lower revenue, but higher earnings than Precision BioSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.06M	4.77	-$45.72M	-$2.80	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Precision BioSciences beats Keen Vision Acquisition on 7 of the 12 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Tonix Pharmaceuticals?

Keen Vision Acquisition (NASDAQ:KVAC) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Keen Vision Acquisition has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Keen Vision Acquisition's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 80.28%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tonix Pharmaceuticals had 6 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 0 mentions for Keen Vision Acquisition. Tonix Pharmaceuticals' average media sentiment score of 1.28 beat Keen Vision Acquisition's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Tonix Pharmaceuticals	Positive

51.7% of Keen Vision Acquisition shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Keen Vision Acquisition has higher earnings, but lower revenue than Tonix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A

Summary

Tonix Pharmaceuticals beats Keen Vision Acquisition on 8 of the 12 factors compared between the two stocks.

Get Keen Vision Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KVAC vs. The Competition

Export

Metric	Keen Vision Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.37M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	N/A	11.62	273.16	25.45
Price / Sales	N/A	1,291.80	604.48	76.58
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	N/A	16.53	12.98	6.14
Net Income	N/A	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	-13.13%	9.80%	7.08%	4.13%
1 Year Performance	-0.90%	55.66%	24.67%	15.17%

Keen Vision Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
AKBA Akebia Therapeutics	2.3498 of 5 stars	$0.94 +3.7%	$3.75 +299.0%	-72.0%	$251.20M	$236.20M	N/A	430
PRQR ProQR Therapeutics	4.1315 of 5 stars	$2.32 -1.3%	$7.50 +223.3%	+1.8%	$247.60M	$17.99M	N/A	180	News Coverage
RNA Avidity Biosciences	1.8527 of 5 stars	$13.98 +0.9%	$63.85 +356.7%	-70.7%	$239.14M	$35.84M	N/A	190
DTIL Precision BioSciences	2.9307 of 5 stars	$8.40 -1.1%	$32.25 +283.9%	+58.8%	$234.34M	$34.26M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KVAC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keen Vision Acquisition (KVAC) Competitors

KVAC vs. AKBA, PRQR, RNA, DTIL, and TNXP

How does Keen Vision Acquisition compare to Akebia Therapeutics?

Summary

How does Keen Vision Acquisition compare to ProQR Therapeutics?

Summary

How does Keen Vision Acquisition compare to Avidity Biosciences?

Summary

How does Keen Vision Acquisition compare to Precision BioSciences?

Summary

How does Keen Vision Acquisition compare to Tonix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC vs. The Competition

Keen Vision Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keen Vision Acquisition (KVAC) Competitors

KVAC vs. AKBA, PRQR, RNA, DTIL, and TNXP

How does Keen Vision Acquisition compare to Akebia Therapeutics?

Which has preferable earnings & valuation, AKBA or KVAC?

Which has more volatility & risk, AKBA or KVAC?

Do analysts recommend AKBA or KVAC?

Does the media refer more to AKBA or KVAC?

Do institutionals and insiders believe in AKBA or KVAC?

Is AKBA or KVAC more profitable?

Summary

How does Keen Vision Acquisition compare to ProQR Therapeutics?

Do insiders and institutionals believe in PRQR or KVAC?

Which has more risk & volatility, PRQR or KVAC?

Does the media prefer PRQR or KVAC?

Do analysts rate PRQR or KVAC?

Which has better earnings & valuation, PRQR or KVAC?

Is PRQR or KVAC more profitable?

Summary

How does Keen Vision Acquisition compare to Avidity Biosciences?

Do institutionals & insiders have more ownership in KVAC or RNA?

Is KVAC or RNA more profitable?

Which has preferable valuation and earnings, KVAC or RNA?

Do analysts prefer KVAC or RNA?

Does the media favor KVAC or RNA?

Summary

How does Keen Vision Acquisition compare to Precision BioSciences?

Does the media refer more to DTIL or KVAC?

Which has more risk and volatility, DTIL or KVAC?

Do analysts rate DTIL or KVAC?

Is DTIL or KVAC more profitable?

Do institutionals and insiders have more ownership in DTIL or KVAC?

Which has better valuation and earnings, DTIL or KVAC?

Summary

How does Keen Vision Acquisition compare to Tonix Pharmaceuticals?

Is KVAC or TNXP more profitable?

Do analysts prefer KVAC or TNXP?

Does the media favor KVAC or TNXP?

Do insiders and institutionals hold more shares of KVAC or TNXP?

Which has more volatility & risk, KVAC or TNXP?

Which has better valuation and earnings, KVAC or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC vs. The Competition

Keen Vision Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools